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Abstract. Substance R an 11-amino acid neuropeptide, 
has an important role in modulating pain transmission 
through neurokinin 1 and 2 receptors. Substance P and 
other tachykinins may also play a role in the pathogene- 
sis of inflammatory diseases. In this study we present 
the results concerning the metabolism of the substance P 
analogue [1HIn-DTPA-Argl]-substance P in man, as well 
as the visualization of the thymus in patients with im- 
mune-mediated diseases. Twelve selected patients were 
investigated, comprising five with inflammatory bowel 
disease, one with ophthalmic Graves' disease, one with 
sclerosing cholangitis, one with Sj6gren's yndrome, one 
with rheumatoid arthritis, one with systemic lupus ery- 
thematosus and two with myasthenia gravis. During and 
after intravenous administration of 150-250 MBq 
(2.5-5.0 gg) [lllIn-DTPA-Arg~]-substance R blood pres- 
sure, heart rate and oxygen saturation were monitored. 
Radioactivity was measured in blood, urine and faeces 
during the 48 h after injection. Planar and single-photon 
emission tomographic mages were obtained 4 and 24 h 
after injection. After administration of [llqn-DTPA- 
Argl]-substance R a transient flush was observed in all 
patients. Degradation of [IllIn-DTPA-Argl]-substance P 
started in the first minutes after administration, resulting 
in a half-life of 10 min for the total plasma radioactivity, 
and of 4 min for the intact radiopharmaceutical, as iden- 
tified with high-performance liquid chromatography. 
Urinary excretion accounted for >95% of the radioactivi- 
ty within 24 h post injection, and up to 0.05% was found 
in the faeces up to 60 h. In all patients uptake of radioac- 
tivity was found in the areolae mammae (in women), liv- 
er, spleen, kidneys and urinary bladder. In eight patients 
a high uptake of [lllIn-DTPA-Argi]-substance P was ob- 
served in the thymus. We conclude that, despite its short 
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half-life, [~liIn-DTPA-Argl]-substance P, a new radio- 
pharmaceutical, can be used to visualize the thymus. 
This may contribute to the investigation of the role of 
thymus in immune-mediated diseases. In addition, in- 
flammatory sites in various diseases could be visualized. 
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Introduction 
Substance P is an 11-amino acid neuropeptide and is 
known as a powerful member of a family of tachykinins 
characterized by the C terminal sequence Phe-X-Gly- 
Leu-Met-NH 2 [1]. It has been well established that sub- 
stance P plays an important role in modulating pain 
transmission from peripheral and central primary affer- 
ents through neurokinin 1 and 2 receptors. Substance P 
and other tachykinins may also play a role in the patho- 
genesis of inflammatory diseases [2-7]. Substance P has 
been shown to induce degranulation f mast cells in vit- 
ro, to regulate chemotaxis, torelease lysosomal enzymes 
from macrophages, and to regulate xpansion of T and B 
cells and production of immunoglobulins [8-11]. The 
thymus eems to be involved in immune-mediated dis- 
eases. Lymphofollicular hyperplasia of the thymus has 
been described in autoimmune diseases uch as myas- 
thenia gravis, systemic lupus erythematosus, scleroder- 
ma, rheumatoid arthritis, Hashimoto's thyroiditis and 
Sj6gren's yndrome [12-15]. 
Recently, substance P was detected in the outer cortex 
of the thymus and in the peptidergic neurons that inner- 
vate the thymus [16, 17]. Specific substance P binding 
sites were found in the rat thymus in association with the 
vessels and the medulla [18]. Large numbers of high-af- 
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finity substance P receptors were found in surgical spec- 
imens obtained from patients with inflammatory bowel 
disease. The substance P binding neurokinin 1 receptor 
is expressed by arterioles and venules located in the sub- 
mucosa, muscularis mucosa, external longitudinal mus- 
cle and serosa [4]. 
We developed a scintigraphic technique using an indi- 
um-I l l  labelled substance P analogue, [lUIn-DTPA- 
Argl]-substance R to visualize affected tissues in im- 
mune disorders, e.g. the thymus. In this study results are 
presented concerning the metabolism of ~lqn-labelled 
[DTPA-Argl]-substance P and the scintigraphic detec- 
tion of the thymus in immune-mediated diseases. This 
may contribute to our understanding of the role of the 
thymus in immune disorders. 
Materials and methods 
Patients. Twelve selected patients were investigated (with in- 
formed consent), five with inflammatory bowel disease, one with 
ophthalmic Graves' disease, one with sclerosing cholangitis, one 
with Sj6gren's yndrome, one with rheumatoid arthritis, two with 
myasthenia gravis and one with systemic lupus erythematosus. 
The diagnosis was established according to the clinical presenta- 
tion and histopathological examination of gastrointestinal biopsies 
in the patients with inflammatory bowel disease and by liver biop- 
sy and endoscopic retrograde cholangiopancreatography in the pa- 
tient with sclerosing cholangitis. In rheumatoid arthritis, Sj6gren's 
syndrome and systemic lupus erythematosus the diagnosis was 
made according to the internationally accepted iagnostic riteria. 
The patient with Graves' disease had a lowered serum thyroid- 
stimulating hormone concentration and elevated serum free thy- 
roxine and specific thyroid-stimulating immunoglobulin concen- 
trations. Uptake of radioactivity was investigated in six control pa- 
tients, three with carcinoid tumours, one with carcinoma of the 
lung and two with malignant lymphomas. These patients received 
no oncological treatment, nor were they immunocompromised. 
Radiopharmaceuticals. [DTPA-Argl]-substance P was labelled 
with 11qnC13 (370 MBq/ml in HC1, pH 1.5-1.9, Mallinckrodt, 
Petten, The Netherlands), up to a specific activity of 150 MBq 
11 qn per gg [DTPA-Argl]-substance E Quality control by instant 
thin-layer chromatography (ITLC, Silica-gel) and SEP-PAK Cls 
reversed-phase extraction were performed essentially as described 
previously [19, 20]. High-performance liquid chromatography 
(HPLC) was done using a Waters 600E multisolvent delivery 
system, connected to a gBondapak C18 reversed-phase column 
(300x3.9 ram, particle size 10 gin). Elution was carried out at a 
flow of 1.5 ml per minute with a linear gradient of 10%-50% ace- 
tonitrile in 0.1% trifluoroacetic acid in 30 min, and the latter com- 
position was kept constant for another 5 min. The radiochemical 
purity of the radiolabelled substance P analogue was greater than 
98%. Although it is not excluded that additional groups of the 
peptide participate in 111in complexation, the labelled product is 
referred to as [11qn-DTPA-Argll-substance R The compound was 
stable for more than 4 h in the presence of the quencher gentisic 
acid at a final concentration f 2 mg per ml and was competitive 
in radioligand isplacement assays [19]. 
Substance P receptor imaging. In our study 2.5-5.0 gg [111In- 
DTPA-Argl]-substance P (150-200 MBq) was infused intrave- 
nously in 10 min. In all patients blood pressure, heart rate and 
oxygen saturation of the blood were monitored. Planar and single- 
photon emission tomographic (SPET) images were obtained with 
a large field of view gamma camera equipped with a medium-en- 
ergy parallel-hole collimator. SPET analysis was performed with a 
Wiener filter on original data. Preset time for images obtained 4, 
24 and 48 h after injection of [1~ qn-DTPA-Argl]-substance P was 
15 rain. Planar images were obtained from the head and neck, 
chest, upper abdomen and lower abdomen. SPET studies were 
performed 4 h or 24 h after injection of the radiopharmaceutical. 
Substance P receptor autoradiography. Substance P receptor auto- 
radiography was performed as previously described [21, 22]. Io- 
dine-125 labelled Bolton-Hunter substance P (BHSP) was used as 
ligand (2000 Ci/mmol; Anawa, Wangen, Switzerland). The slide- 
mounted tissue sections were allowed to reach room temperature 
and then placed for 15 rain in a pre-incubation medium of 
50 retool/1 Tris-HC1, pH 7.4, at room temperature. The sections 
were then incubated for 60 min, always at room temperature, in a 
solution of 50 retool/1 Tris-HC1 pH 7.4, containing BSA 
(200 rag/l), chymostatin (2 mg/1), leupeptin (4 rag/l), bacitracin 
(40 rag/l), MnC12 5 mmol/1 and 50 pmol 125I-BHSR To estimate 
non-specific binding, paired serial sections were incubated as de- 
scribed above but 1 gmol/1 SP (Bachem, Bubendorf, Switzerland) 
was added to the incubation medium. Following this incubation 
the slides were rinsed 4 times, for 30 s each time, in ice-cold 
50 mmol/1 Tris-HC1, pH 7.4, dipped in ice-cold distilled water, 
then quickly dried in a refrigerator under a stream of cold air. Sec- 
tions were exposed to [3H]-Ultrafilm (Amersham, UK) for 1 
week. 
Measurement ofradioactivity in blood, urine and faeces. Radioac- 
tivity in blood, urine and faeces was measured with an LKB-1282- 
Compugamma system or a GeLi-detector equipped with a multi- 
channel analyser (Series 40, Canberra). Blood was collected in 
EDTA-containing tubes and immediately cooled on ice. Since 
substance P is readily metabolized by various enzymes in blood, 
samples were immediately centrifuged at 0°C, and plasma was 
fractionated on SEP-PAK C18 columns. Using the separation tech- 
nique described previously [20], [llqn-DTPA-Argl]-substance P 
binds to SEP-PAK C18 stationary phase and is only eluted with 
ethanol, while Ilqn-DTPA is not retained on SEP-PAK C18 col- 
umns. The radioactivity in plasma and urine samples, which was 
eluted with ethanol from the SEP-PAK Cls column, is termed pep- 
tide-bound radioactivity, but was not further characterized. Blood 
samples were collected irectly before and 2, 5, 10, 20 and 40 rain 
and 1, 4, 20 and 48 h after infusion. Urine was collected from the 
time of injection, initially at two intervals of 3 h and thereafter in 
intervals of 6 h until 48 h after injection. If feasible, faeces was 
collected until 72 h after injection. The chemical status of the ra- 
dionuclide in blood and urine was analysed as a function of time 
using the SEP-PAK C18, HPLC and PD-10 gel filtration tech- 
niques as described previously [19, 20]. 
Results 
After administration of [IllIn-DTPA-Argl]-substance P a 
transient flush was observed in all patients. In one pa- 
tient with Crohn's disease and anaemia, significant hy- 
potension was observed associated with bradycardia. 
This patient recovered after 30 s in Trendelenburg's po- 
sition, suggesting the presence of a vasovagal collapse. 
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Fig. 1. Total plasma (O), peptide-bound (A) and cell-bound (©) 
radioactivity during the 48 h after injection 
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Fig. 2. Cumulative urinary excretion pattern of total (Q) and pep- 
tide-bound (O) radioactivity dm'ing the 48 h after injection. The 
intersected line (A) shows the radioactivity inthe urinary bladder 
In Fig. 1 the time courses of total and peptide-bound 
radioactivity in plasma are presented until 50 h after ad- 
ministration. The average plasma radioactivity decreased 
rapidly after injection of [~1 lin_DTPA_Argl]_substanc e R 
Degradation of [nlIn-DTPA-Argl]-substance P started 
in the first minutes after administration, resulting in a 
half-life of 10 rain for total plasma radioactivity and of 
4 rain for the intact radiopharmaceutical, s identified 
with HPLC. Renal excretion resulted in the excretion of 
>90% of the radioactivity in the urine within 24 h after 
injection, as shown in Fig. 2. Up to 0.05% was found in 
the faeces until 60 h after injection. 
In all patients uptake of radioactivity was found in the 
liver, spleen and kidneys, as shown in Fig. 3. In addition, 
the urinary bladder, in women the areolae mammae, in 
four patients the lungs and in three patients the parotid 
glands were visualized. The uptake of radioactivity at 
these sites was supposed to be due to receptor binding 
(areolae, parotid glands and spleen) or to metabolism 
(liver, lungs, kidneys and urinary bladder) of the radio- 
pharmaceutical. Deposition of radioactivity at other sites 
was considered to be due to other causes, which may be 
disease related (see Table 1). In eight patients a high up- 
take of [lnin_DTPA_Argl]_substanc e p was found in the 
thymus. The highest uptake of radioactivity in the thy- 
mus was observed in a patient with sclerosing cholangi- 
tis (Fig. 4). Computed tomographic scanning of the tho- 
rax confirmed an enlarged thymus. In the patients with 
systemic lupus erythematosus, ophthalmic Graves' dis- 
ease and rheumatoid arthritis, and in two patients with 
inflammatory bowel disease, the thymus was visualized 
as well. In one patient with myasthenia gravis the thy- 
mus was visualized. In contrast, the other patient with 
myasthenia gravis, who was receiving high-dose cortico- 
steroids, was negative at scintigraphy. No uptake of ra- 
Fig. 3. Substance P receptor scintigraphy of the upper abdomen 
and thorax in a patient with Crohn's disease (patient 9). Both kid- 
neys, liver, spleen and a slight spot in the thorax resembling the 
thymus were visualized. (Anterior view, 24 h after injection) 
Fig. 4. Accumulation of radioactivity in the thymus of a patient 
with sclerosing cholangitis, 24 h after injection (anterior view) 
Fig. 5. Substance P receptor scintigraphy in a patient with 
Sj6gren's yndrome (patient 13). In this patient uptake of radioac- 
tivity was found in the parotid glands, nose and thymus. (Anterior 
view, 24 h post injection) 
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TabLe 1. Substance P receptor scintigraphy: positive sites in controls and patients with autoimmune diseases 
Patient Sex Age Diagnosis Region Sites positive by scintigraphy a 
1511 
1 M 56 Hodgkin's disease WB Mouth, nose, lungs 
2 M 34 Non-Hodgkins lymphoma WB Lungs 
3 M 55 Carcinoid WB Lungs 
4 M 36 Carcinoid WB 
5 M 33 Carcinoid WB Parotid glands, mouth, nose 
6 M 62 Bronchus carcinoma WB Mouth, nose 
7 F 24 Crohn's disease WB Mouth, nose, abdominal spot 
8 F 60 Crohn's disease WB Thymus 
9 F 30 Crohn's disease WB Thymus, parotid glands, abdominal spot 
10 M 40 Ulcerative colitis Partial 
11 F 39 Ulcerative colitis WB 
12 M 25 Sclerosing cholangitis WB Thymus, abdominal spots 
13 F 46 Sj6gren's yndrome Partial Thymus, parotid glands 
14 F 72 Rheumatoid athritis Partial Thymus, joints 
15 F 34 Graves' disease Partial Thymus, eye 
16 F 32 Systemic lupus erthematosus Partial Thymus, lungs 
17 F 25 Myasthenia gravis Partial Thymus 
18 M 48 Myasthenia gravis Partial 
M, Male; F, female; WB, whole body 
a In all patients uptake was found in the liver, spleen, kidneys and urinary bladder 
dioactivity in the thymus or turnouts was observed in the 
patients with carcinoid tumours (n=3), lung carcinoma 
(n=l) or malignant lymphomas (n=2). 
In addition to the thymus, in the patient with 
SjOgren's syndrome, the affected parotid glands showed 
a very high uptake of radioactivity (Fig. 5). In the patient 
with unilateral ophthalmic Graves' disease, high uptake 
of radioactivity was observed in the affected eye. The 
patient with rheumatoid arthritis revealed uptake of ra- 
dioactivity in the affected joints. In two out of five pa- 
tients with inflammatory bowel disease, accumulation of 
radioactivity was found at the sites of inflammation. 
In vitro detection of specific substance P receptors in 
the thymus from patients with myasthenia gravis was 
performed with substance P receptor autoradiography. 
As seen in Fig. 6, a high density of specific substance P 
binding sites was identified in this tissue. The localiza- 
tion of the receptors is not yet completely clear, but 
counterstaining of the sections for factor VIII immuno- 
histochemistry suggests that the localization of some of 
the substance P receptors corresponds to that of the 
small vessels. However, it is probable that lymphoreticu- 
lar cells also contair~ substance P receptors. 
Discussion 
Substance P is found in the central nervous system as 
well as in peripheral neuronal circuits. In the peripheral 
nervous system substance P is found in the primary af- 
ferent neurons (A-delta pain fibres and C fibres), which 
are involved in the transmission of noxious stimuli. Bio- 
active substance P has been infused intravenously in hu- 
mans in doses of 0.5-1.5 pmol kg -1 min -1 over 60 min or 
0.5-8.0 pmol kg -1 rain -1 over 20 min without serious 
side-effects [23, 24]. A very short half-life of 1.6 min 
was measured, indicating a very high metabolic lear- 
ance. In normal plasma substance P is degraded by enzy- 
matic hydrolysis involving multiple proteases [25]. In 
this study the [DTPA-Argl]-substance P was injected in 
patients with immune-mediated diseases. In one out of 
12 patients hypotension was observed, with the clinical 
impression that a vasovagal collapse caused the hypoten- 
sion. After administration of [lliIn-DTPA-Argl]-sub- 
stance P a transient flush was observed in all patients. 
Flushing by substance P is explained by vasodilatation 
of the blood vessels of the skin and indicates biological 
activity [24]. 
A very short half-life of 10 min for plasma radioac- 
tivity and of 4 min for the intact radiopharmaceutical 
was measured. Radioactivity was excreted almost exclu- 
sively by the kidneys, resulting in a low accumulation of 
radioactivity in the intestinal tract. Despite the high deg- 
radation rate of this radiopharmaceutical, it could visual- 
ize affected tissues. In eight patients with immune-medi- 
ated diseases the thymus was visualized. The present au- 
toradiographic data undoubtedly showed the presence of 
specific substance P receptors in the thymus from two 
non-scanned patients with an autoimmune disease. In the 
control patients, the thymus could not be visualized, sug- 
gesting a high receptor expression in immune-mediated 
diseases. Substance P receptors have recently been re- 
ported to be present in the rat thymus, but their role is 
still obscure [18]. Substance P has been identified in 
nerve fibres of sensory origin in the thymus. The outer 
cortex of the human thymus contains a one- to two-cell- 
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Fig. 6A-C. Substance P receptors in the thymus of a patient with 
myasthenia gravis, detected with in vitro receptor autoradiogra- 
phy. A Histological section, stained for factor VIII-like immuno- 
reactivity. A high density of vessels urrounds a nodular aggregate 
of small ymphocytes, enclosing lymphatic follicles with germinal 
centres, and less densely cellular areas with Hassall's corpuscles. 
Bar=l mm. B Total binding of 125I-BHSR Vessel-rich regions are 
labelled. Some lymphoreticular cells may also be labelled. C Non- 
specific binding 
thick layer that is immunoreactive with antisera gainst 
substance R In this region the most immature and re- 
cently migrated thymocytes are found, emphasizing the 
role of neuropeptides in regulating the microenviron- 
ment for T cell development [16]. The gene encoding 
both substance P and neurokinin A was shown to be ex- 
pressed in rat thymus, especially in a subpopulation of 
cells in the medulla [26]. 
The thymus is known to play an important role in my- 
asthenia gravis. The negative scintigram in one of the 
patients with myasthenia gravis may have been related to 
the use of high-dose corticosteroids, which are known to 
cause involution of the thymus. In 70% of cases, micros- 
copy of thymuses of patients with myasthenia gravis re- 
vealed follicular hyperplasia of the medulla, containing 
germinal centres resembling an activated lymph node 
[27, 28]. It may be that primary sensitization against he 
acetylcholine r ceptor, which plays a crucial role in my- 
asthenia gravis, occurs in the thymus. The reason why 
substance P receptors are present in the thymus of pa- 
tients with immune-mediated disease, as suggested in 
our patients, is obscure. However, their presence may 
mean that a similar process of sensitization as is hypoth- 
esized in myasthenia gravis takes place in other autoim- 
mune diseases as well. 
Besides the thymus, sites of inflammation i two pa- 
tients with inflammatory bowel disease, the affected or- 
bit in ophthalmic Graves' disease, the salivary glands in 
Sj6gren's yndrome and the joints in rheumatoid arthritis 
were visualized. Although in patients with inflammatory 
bowel disease accumulation of radioactivity due to gut 
stenosis cannot be ruled out, the very low excretion of 
[111in_DTPA_Argl]_substanc e p into the bowel (<0.05%) 
does not favour this explanation. Therefore, this accu- 
mulation is most likely due to the presence of substance 
P receptors at the sites of inflammation i these patients, 
though we have no autoradiographic confirmation from 
the "scanned" patients. Substance P is supposed to be in- 
volved in inflammatory bowel disease, and upregulation 
of receptor binding sites at venules and muscle was pre- 
viously shown by autoradiography [4]. In these patients 
a high expression of substance P receptors was observed 
in comparison with control patients (1000-2000 times 
normal). Furthermore, substance P receptors have been 
reported in inflammatory synovitis in rat and humans 
[6]. 125I-labelled substance P binding to microvascular 
endothelium paralleled the distribution of substance P
immunoreactive n rves and had the characteristics of the 
neurokinin 1receptor [6]. 
In this study we have presented our preliminary re- 
sults concerning the use of [111In-DTPA-Argl]-substance 
P as a new radiopharmaceutical with a very short half- 
life in the circulation. The thymus, which is usually in- 
voluted after puberty, expressed enough substance P re- 
ceptors to allow in vivo visualization. The role of the 
thymus in autoimmune diseases is obscure, but enlarge- 
ment of the thymus has been described in these diseases. 
Further investigations are necessary to evaluate the role 
of substance P receptor expression in the thymus in 
these diseases. In addition, inflammatory sites in various 
diseases could be visualized by substance P receptor 
scintigraphy. 
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